Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Microbleeds and Genetic Risk Factors to Predict the Risk of Intracranial Haemorrhage in Patients Treated With Anticoagulation Following Cardioembolic Stroke Due to Atrial Fibrillation
Brief Summary: Study I: CROMIS-2 (AF) Prospective cohort study of patients anticoagulated after cardioembolic stroke An observational inception cohort study (n=1425) of patients throughout the United Kingdom (UK) - (79 hospitals) started on best practice oral anticoagulant (without prior use) for presumed cardioembolic ischaemic stroke due to non-valvular AF with follow up for the occurrence of intracerebral haemorrhage (ICH) and ischaemic stroke for an average of two years. The main baseline exposures (risk factors of interest) are the presence of cerebral microbleeds (CMBs) on magnetic resonance imaging (MRI), and genetic polymorphisms in candidate genes with potential functional relevance to ICH risk.

Study II: CROMIS-2 (ICH) Observational and genetics study of intracerebral haemorrhage The investigators will also recruit 600 patients admitted to participating centres with ICH (with a target of at least 300 anticoagulant-related ICH cases) and collect DNA to increase the power of the genetic studies. The investigators will collect clinical and imaging data from these ICH cases to investigate risk factors associated with anticoagulant-related ICH compared to non anticoagulant-related ICH.


Options:
A: Arm Label: Cilostazol+ Probucol; Type: EXPERIMENTAL; Interventions: Drug: Cilostazol, Drug: Probucol, Drug: placebo of aspirin, Device: ankle-brachial index (ABI), Device: intima-medial thickness (IMT), Device: new asymptomatic brain hemorrhage, Device: new ischemic lesions on follow-up FLAIR images | Arm Label: Aspirin + Probucol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Probucol, Drug: Aspirin, Drug: placebo of cilostazol, Device: ankle-brachial index (ABI), Device: intima-medial thickness (IMT), Device: new asymptomatic brain hemorrhage, Device: new ischemic lesions on follow-up FLAIR images | Arm Label: Cilostazol; Type: EXPERIMENTAL; Interventions: Drug: Cilostazol, Drug: placebo of aspirin, Device: ankle-brachial index (ABI), Device: intima-medial thickness (IMT), Device: new asymptomatic brain hemorrhage, Device: new ischemic lesions on follow-up FLAIR images | Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: placebo of cilostazol, Device: ankle-brachial index (ABI), Device: intima-medial thickness (IMT), Device: new asymptomatic brain hemorrhage, Device: new ischemic lesions on follow-up FLAIR images | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): Cilostazol, Cilostazol+ Probucol | Intervention Type: DRUG; Name: Probucol; Assigned to Arm(s): Aspirin + Probucol, Cilostazol+ Probucol | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin, Aspirin + Probucol | Intervention Type: DRUG; Name: placebo of cilostazol; Assigned to Arm(s): Aspirin, Aspirin + Probucol | Intervention Type: DRUG; Name: placebo of aspirin; Assigned to Arm(s): Cilostazol, Cilostazol+ Probucol | Intervention Type: DEVICE; Name: ankle-brachial index (ABI); Assigned to Arm(s): Aspirin, Aspirin + Probucol, Cilostazol, Cilostazol+ Probucol | Intervention Type: DEVICE; Name: intima-medial thickness (IMT); Assigned to Arm(s): Aspirin, Aspirin + Probucol, Cilostazol, Cilostazol+ Probucol | Intervention Type: DEVICE; Name: new asymptomatic brain hemorrhage; Assigned to Arm(s): Aspirin, Aspirin + Probucol, Cilostazol, Cilostazol+ Probucol | Intervention Type: DEVICE; Name: new ischemic lesions on follow-up FLAIR images; Assigned to Arm(s): Aspirin, Aspirin + Probucol, Cilostazol, Cilostazol+ Probucol
B: Arm Label: Telemetric Bluetooth-enabled home BP monitors; Type: EXPERIMENTAL; Interventions: Device: A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci | Arm Label: Standard clinical care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci; Assigned to Arm(s): Telemetric Bluetooth-enabled home BP monitors
C: Arm Label: Study I (AF); Type: N/A; Interventions: N/A | Arm Label: Study II (ICH); Type: N/A; Interventions: N/A
D: Arm Label: Triple Pill (active treatment); Type: EXPERIMENTAL; Interventions: Drug: telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg; Assigned to Arm(s): Triple Pill (active treatment) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C